| Abstract: | Although gastrointestinal stromal tumors(GISTs) are rare, with an incidence of 1/100000 per year, they are the most common sarcomas in the peritoneal cavity.Despite considerable progress in the diagnosis and treatment of GIST, about half of all patients are estimated to experience recurrence. With only two drugs,sunitinib and regorafenib, approved by the Food and Drug Administration,selecting treatment options after imatinib failure and coordinating multidisciplinary care remain challenging. In addition, physicians across the Middle East face some additional and unique challenges such as lack ofpublished local data from clinical trials, national disease registries and regional scientific research, limited access to treatment, lack of standardization of care,and limited access to mutational analysis. Although global guidelines set a framework for the management of GIST, there are no standard local guidelines to guide clinical practice in a resource-limited environment. Therefore, a group of 11 experienced medical oncologists from across the Gulf and Levant region, part of the Rare Tumors Gastrointestinal Group, met over a period of one year to conduct a narrative review of the management of GIST and to describe regional challenges and gaps in patient management as an essential step to proposing local clinical practice recommendations. |
